- Home
- SLAI vs PHIO Comparison
SLAI vs PHIO Comparison
Compare SLAI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SLAI
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
Current Price
Company Overview
Basic Information| Metric | SLAI | PHIO |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLAI | PHIO |
|---|---|---|
| Price | $1.06 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 929.5K | 376.5K |
| Earning Date | 02-27-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $0.97 |
| 52 Week High | $8.07 | $4.53 |
Technical Indicators
Market Signals| Indicator | SLAI | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.18 |
| Support Level | N/A | $1.09 |
| Resistance Level | N/A | $1.22 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 57.50 |
Price Performance
Historical ComparisonAbout SLAI SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.